| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid TR primarily targets influenza neuraminidases (NAs), particularly H5N1 and H1N1 neuraminidases, with IC50 values of 10.9 μM and 4.6 μM, respectively. It acts as a broad-spectrum inhibitor against these viral enzymes. The compound also has 5α-reductase inhibitory activity. By inhibiting neuraminidase, it prevents viral release and spread, making it a potential antiviral agent for influenza treatment.
|
|---|---|
| ln Vitro |
In vitro, ganoderic acid TR is a broad-spectrum inhibitor against influenza neuraminidases (NAs), with IC50 values of 10.9 μM (H5N1) and 4.6 μM (H1N1). It shows 5α-reductase inhibitory activity. The compound's antiviral activity is typically evaluated using neuraminidase inhibition assays with purified viral enzymes. Its activity against various influenza strains is assessed to confirm broad-spectrum inhibition. The compound is also studied for its effects on viral replication and host-virus interaction pathways.
|
| ln Vivo |
In vivo activity of ganoderic acid TR has not been extensively characterized in published literature. As a neuraminidase inhibitor, it has potential for treating influenza infections. The compound is studied for potential inhibitory effects on viral replication and host-virus interaction pathways. It is also used as a screening reference molecule and for mechanistic studies investigating molecular pathways modulated by bioactive triterpenoids. Specific in vivo efficacy data, including dosing regimens and animal models, are not detailed in the available literature.
|
| Enzyme Assay |
Cell-free assays for ganoderic acid TR involve measuring its inhibitory activity against influenza neuraminidases. Purified neuraminidase enzymes (H5N1, H1N1) are incubated with varying concentrations of ganoderic acid TR and a fluorogenic substrate. IC50 values (10.9 μM for H5N1, 4.6 μM for H1N1) are determined from dose-response curves. 5α-Reductase inhibitory activity can also be assessed using enzyme-based assays. The compound's chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry.
|
| Cell Assay |
In vitro cellular assays for ganoderic acid TR involve treating influenza virus-infected cells with the compound. Cells are incubated with various concentrations of ganoderic acid TR, and viral replication is assessed by measuring viral RNA or plaque formation. Antiviral efficacy is evaluated by comparing viral titers between treated and untreated cells. Cytotoxicity is assessed using standard cell viability assays to ensure that the observed antiviral effects are not due to cell death. The compound's mechanism of action is studied using time-of-addition assays.
|
| Animal Protocol |
In vivo animal studies for ganoderic acid TR are conducted in mouse models of influenza infection. The compound is administered via various routes including oral gavage or intraperitoneal injection. Viral titers in lung tissues are measured. Survival rates and body weight changes are monitored. Inflammatory markers in serum and lung tissues are assessed. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating antiviral agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ganoderic acid TR include a molecular weight of 468.67 g/mol, molecular formula C30H44O4, and purity ≥98% (HPLC). It has a density of 1.1±0.1 g/cm3, boiling point of 618.6±55.0 °C, and LogP of 5.7. The compound is soluble in DMSO (10 mM). It is typically stored as a powder at -20°C for 3 years or at 4°C for 2 years. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ganoderic acid TR has not been extensively characterized in published literature. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have a favorable safety profile at research doses. Resistance mechanisms may involve metabolic transformations or membrane adaptations altering compound access or stability. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that Ganoderma lucidum contains ganoderic acid (TR), and relevant data is available for reference.
Ganoderic acid TR is a lanostane-type triterpenoid from Ganoderma lucidum and a broad-spectrum inhibitor of influenza neuraminidases (H5N1 IC50 = 10.9 μM; H1N1 IC50 = 4.6 μM). It also has 5α-reductase inhibitory activity. The compound is used in antiviral research, mechanistic studies, and as a screening reference molecule. Ganoderic acid TR is a research tool for studying influenza and triterpenoid bioactivity. |
| Molecular Formula |
C30H44O4
|
|---|---|
| Molecular Weight |
468.668
|
| Exact Mass |
468.323
|
| CAS # |
862893-75-2
|
| PubChem CID |
11442745
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
618.6±55.0 °C at 760 mmHg
|
| Flash Point |
341.9±28.0 °C
|
| Vapour Pressure |
0.0±4.1 mmHg at 25°C
|
| Index of Refraction |
1.563
|
| LogP |
6.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
984
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC/C=C(\C)/C(=O)O)[C@H]1C[C@@H]([C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C)O
|
| InChi Key |
SNZQBBATMLGADX-VVUVUVSISA-N
|
| InChi Code |
InChI=1S/C30H44O4/c1-18(9-8-10-19(2)26(33)34)22-17-25(32)30(7)21-11-12-23-27(3,4)24(31)14-15-28(23,5)20(21)13-16-29(22,30)6/h10-11,13,18,22-23,25,32H,8-9,12,14-17H2,1-7H3,(H,33,34)/b19-10+/t18-,22-,23+,25+,28-,29-,30-/m1/s1
|
| Chemical Name |
(E,6R)-6-[(5R,10S,13R,14R,15S,17R)-15-hydroxy-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1337 mL | 10.6685 mL | 21.3370 mL | |
| 5 mM | 0.4267 mL | 2.1337 mL | 4.2674 mL | |
| 10 mM | 0.2134 mL | 1.0668 mL | 2.1337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
